Needham Reiterates Hold Rating on Medtronic, Inc. (MDT)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- Wall Street ends down as US-Iran peace optimism fades
- eToro to acquire TradeZero for up to $231M to expand in US
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Medtronic, Inc. (mdt) PT Raised to $107 at Evercore ISI
August 19, 2025 4:15 PM EDTEvercore ISI analyst Vijay Kumar raised the price target on Medtronic, Inc. (NYSE: mdt) to $107.00 (from $106.00) while maintaining a Outperform rating.
The analyst comments "Thesis Update: Im in the EU & thought the Caesars phrase (w some tweaks) was apt in... More
Truist Securities Reiterates Hold Rating on Medtronic, Inc. (MDT)
August 19, 2025 8:30 AM EDTTruist Securities analyst Richard Newitter reiterated a Hold rating and $92.00 price target on Medtronic, Inc. (NYSE: MDT).
The analyst comments "MDT's 4.8% organic rev growth was roughly in-line with 4.9% CNS, while higher reported rev (on FX) and (+$0.02 non-op items) drove a slight EPS beat ($1.26 vs CNS $1.23) on roughly... More
Goldman on Medtronic, Inc. (MDT), 'believe investors had expected total organic growth acceleration to follow the strong performance in CAS'
August 19, 2025 8:05 AM EDTGoldman Sachs analyst David Roman reiterated a Sell rating and $78.00 price target on Medtronic, Inc. (NYSE: MDT)
The analyst comments "This morning, Medtronic reported 1QFY26 that on a reported basis exceeded both GSe/Consensus (Visible Alpha consensus Data, unless otherwise noted). On an... More
Raymond James on Medtronic, Inc. (MDT) Earnings: 'All in, this result and guide fell short of our elevated expectations'
August 19, 2025 8:04 AM EDTRaymond James analyst Jayson Bedford reiterated a Market Perform rating and {REMOVEPT} price target on Medtronic, Inc. (NYSE: MDT).
The analyst comments "F1Q revenue beat consensus (by ~2%), but this was due to FX and Other revenue as organic growth of 4.8% y/y... More
Stifel Reiterates Hold Rating on Medtronic, Inc. (MDT)
August 19, 2025 8:01 AM EDTStifel analyst Rick Wise reiterated a Hold rating and $87.00 price target on Medtronic, Inc. (NYSE: MDT).
The analyst comments "Reporting yet another largely as expected quarter, F1Q26 performance was positively just above Consensus for both organic growth and EPS...and this... More
Mizuho on Medtronic, Inc. (MDT): 'Largely Inline Print Likely Overshadowed by New Board Appointees'
August 19, 2025 7:58 AM EDTMizuho analyst Anthony Petrone reiterated an Outperform rating and $100.00 price target on Medtronic, Inc. (NYSE: MDT)
The analyst comments "MDT reported a +$195mn/+$0.03 beat driven by strong performances across Cardiovascular (+$92mn ahead of Street), Diabetes (+22mn ahead of Street) and MedSurg... More
